Preferential Efficacy of Remission Maintenance with HDC/IL-2 in Age Groups of Patients with Chemoresponsive or Normal Karyotype AMLMalin S. Nilsson,Anna Martner,Fredrik B. Thorén,Kristoffer HellstrandBlood(2023)引用 0|浏览6暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要